SAB Biotherapeutics
SABS
SABS
40 hedge funds and large institutions have $2.32M invested in SAB Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
48% less capital invested
Capital invested by funds: $4.45M → $2.32M (-$2.13M)
Holders
40
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$109K | |
| 2 | +$50.2K | |
| 3 | +$48K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$28K |
| 5 |
Jane Street
New York
|
+$17K |
Top Sellers
| 1 | -$64K | |
| 2 | -$30.2K | |
| 3 | -$19K | |
| 4 |
Millennium Management
New York
|
-$18K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.5K |